Ikaria News

FDA ACCEPTS FINAL SECTION OF NDA FILING FOR LUCASSIN®

Jun 12, 2009 Read more

 

IKARIA® TO PRESENT AT 27th ANNUAL JPMORGAN HEALTHCARE CONFERENCE

Jan 8, 2009 Read more

 

IKARIA® NAMED PRIVATE COMPANY OF THE YEAR BY NEW JERSEY TECHNOLOGY COUNCIL

Nov 21, 2008 Read more

 

INHALED NITRIC OXIDE DATA PRESENTED AT EUROPEAN ACADEMY OF PEDIATRICS MEETING

Oct 25, 2008 Read more

 

IKARIA® STRENGTHENS EXECUTIVE LEADERSHIP TEAM

Head of Engineering and Operations Appointed.

Oct 2, 2008 Read more

 

IKARIA® ACQUIRES NORTH AMERICAN RIGHTS TO LUCASSIN® FROM ORPHAN THERAPEUTICS

No Currently Approved Drugs to Treat Hepatorenal Syndrome Type 1 in U.S.

Sept. 2, 2008 Read more

 

 

See more press releases

IKARIA® STRENGTHENS COMMERCIAL OPERATIONS AND HUMAN RESOURCES LEADERSHIP

Appoints Stephen Ross Senior Vice President of Commercial Operations and James Briggs Senior Vice President of Human Resources.

Aug. 25, 2008 Read more

 

IKARIA® RECEIVES FDA ORPHAN DRUG DESIGNATION FOR INHALED CARBON MONOXIDE FOR DELAYED GRAFT FUNCTION IN SOLID ORGAN TRANSPLANTS

July 28, 2008 Read more

 

IKARIA®’S INOFLO (NITRIC OXIDE) FOR INHALATION APPROVED IN JAPAN

Ikaria to Market and Distribute INOflo via Partnership with Air Water Incorporated and Sumitomo Seika Chemicals

July 21, 2008 Read more

 

IKARIA® STRENGTHENS RESEARCH & DEVELOPMENT TEAM

Appoints Dr. Deborah Petrowsky Vice President of Medical Affairs and Dr. Steven Knapp Vice President of Regulatory Affairs.

July 1, 2008 Read more

 

IKARIA® INTRODUCES DR. MICHAEL COOREMAN AS VICE PRESIDENT OF TRANSLATIONAL MEDICINE

Translational Medicine Department Strengthens Research & Development Team

June 24, 2008 Read more

 

IKARIA®’S INOFLO (NITRIC OXIDE) FOR INHALATION TO BE OFFICIALLY APPROVED IN JAPAN

June 18, 2008 Read more

 

IKARIA® COMPLETES DOSING OF PHASE 1A CLINICAL STUDY FOR IK-1001(SODIUM SULFIDE) FOR INJECTION

May 19, 2008 Read more

 

LOTA ZOTH ELECTED TO IKARIA® BOARD AND NAMED AUDIT COMMITTEE CHAIR

Jan. 22, 2008 Read more

 

IKARIA® WINS SECOND CONSECUTIVE AARC ZENITH AWARD

at 53rd International Respiratory Congress

Jan. 17, 2008 Read more

 

IKARIA® APPOINTS DANIEL TASSÉ AS PRESIDENT AND CHIEF EXECUTIVE OFFICER

Former CEO David Shaw Named Executive Chairman and Chairman of the Board.

Jan. 9, 2008 Read more

 

IKARIA® TO PRESENT AT 26th ANNUAL JPMORGAN HEALTHCARE CONFERENCE

Jan. 3, 2008 Read more

 

IKARIA®’S INOMAX (NITRIC OXIDE) FOR INHALATION APPROVED IN AUSTRALIA

Expands global reach of Ikaria with approval of first pharmaceutical gas in Australia to help newborns who suffer from hypoxic respiratory failure.

November 27, 2007 Read more

 

IKARIA® NAMES EXECUTIVE VICE PRESIDENT OF RESEARCH AND DEVELOPMENT

October 1, 2007 Read more

 

IKARIA® FOUNDING SCIENTIST NAMED 2007 MACARTHUR FELLOW

September, 26, 2007 Read more

 

NEW STUDY SHOWS PROMISE FOR HYDROGEN SULFIDE IN REDUCING HEART-ATTACK DAMAGE, IKARIA® ANNOUNCES

Study led by Albert Einstein College of Medicine researchers published in major scientific journal

September 25, 2007 Read more

 

MATTHEW BENNETT JOINS IKARIA® AS VICE PRESIDENT AND GENERAL COUNSEL

July 23, 2007 Read more

 

DAVID SHAW TO SERVE AS PRESIDENT OF IKARIA® AND INO THERAPEUTICS

May 2, 2007 Read more

 

IKARIA® AND INVESTOR GROUP CLOSE TRANSACTION TO ACQUIRE INO THERAPEUTICS FROM LINDE IN $670 MILLION CASH AND STOCK MERGER, CREATING A WORLD LEADER IN CRITICAL CARE THERAPEUTICS

March 28, 2007 Read more

 

IKARIA® ANNOUNCES IN-LICENSING OF “THYRONAMINE TECHNOLOGY” FROM THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO AND OREGON HEALTH & SCIENCE UNIVERSITY

February 25, 2007 Read more

 

INO THERAPEUTICS WINS ZENITH AWARD

December, 2006 Read more